Login to get immediate access to this content.
LoginSpeaker: Luca Gianni, Italy
#ESMO23: Breaking Science in Breast Cancer Video Series
Highlights on the treatment of High Risk TNBC: The NeoTRIP Michelangelo study
Abstract discussed:
- LBA19 - Event-free survival (EFS) analysis of the neoadjuvant treatment with or without atezolizumab in high-risk triple negative breast cancer (TNBC). NeoTRIP Michelangelo randomized study
Series objectives: To provide oncologists all over the world with succinct summaries of the most important study results on Breast Cancer, delivered by leading experts in video interviews.
Our selection gives a landscape view of the important scientific breakthroughs in the molecular classification, prognostication and prediction, state of art management and precision oncology in Breast Cancer.
The study results covered, and speakers in this video series, have been selected exclusively by ESMO.
Published on 30 Oct 2023
